RxDoctor Payments Data

Blake Barraza, MD

Family Medicine · Laredo, TXNPI 1578120895

Payments from drug & device makers

$1,523in general payments, 2019–2025

Across 43 payments — averaging $35.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$386
  • Novo Nordisk$282
  • AstraZeneca$262
  • Amgen$188
  • AbbVie$125
  • Sonex Health, Inc.$105
  • plus $176 from 5 others

What the payments were for

  • Food & beverage$1,523100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,523 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$3,594
Medicare patients
22
Services billed
36

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide42$44,638
MounjaroTirzepatide12$16,320
FarxigaDapagliflozin Propanediol14$14,747
JardianceEmpagliflozin14$14,635
Amlodipine-ValsartanAmlodipine Besylate/Valsartan15$1,258
Atorvastatin Calcium92$883
Rosuvastatin Calcium22$563
Levothyroxine Sodium38$418
Omeprazole22$407
Metoprolol Succinate19$348
Metformin Hcl ErMetformin Hcl21$252
Olmesartan Medoxomil17$227
Losartan Potassium17$158
ClopidogrelClopidogrel Bisulfate14$139
Pantoprazole Sodium17$132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$282$44,63842 claims
Lilly USA, LLCMounjaro$386$16,32012 claims
AstraZenecaFarxiga$262$14,74714 claims
Boehringer IngelheimJardiance$20$14,63514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Laredo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →